ClinicalTrials.gg
RecruitingNCT05296304Updated Nov 18, 2026

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

A Phase 1 interventional study of Bexarotene and Total Skin Electron Beam (TSEB) in Cutaneous T-cell Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionMycosis FungoidesRegistry: Lymphoma, T-Cell, CutaneousReclassifiedWhy we changed it
Registry
Lymphoma, T-Cell, Cutaneous — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mycosis Fungoides
Why
  1. The study's title name Mycosis Fungoides, a narrower term within Lymphoma, T-Cell, Cutaneous.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Mycosis Fungoides by Memorial Sloan Kettering Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Mycosis Fungoides · Memorial Sloan Kettering Cancer Center.

Started
2022
the only one that year
Phase 1
6 of 13
1 open now
Registered
12th of 13
by date

Among the 13 studies in Mycosis Fungoides by Memorial Sloan Kettering Cancer Center, this one is the only one that started in 2022, is one of 6 in phase 1, and was the 12th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

2 of the 13 studies in Mycosis Fungoides by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Mycosis Fungoides by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).

Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin.

The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

03

Conditions studied

  • Cutaneous T-cell Lymphoma

Browse trials for

Keywords

  • Bexarotene
  • Radiotherapy
  • Mycosis Fungoides
  • 21-501
04

In context

Mycosis Fungoides Reclassified

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

This study's planned enrollment of 20 is below the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.

Browse Mycosis Fungoides studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Mycosis Fungoides, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, T-Cell, Cutaneous. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • confirmed cutaneous T-cell lymphoma consistent with mycosis fungoides (MF) based on done or reviewed at MSKCC
  • Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible. Patients who have not had prior systemic therapies and /relapsed patients are eligible.
  • Baseline mSWAT score of at least 10
  • Stable topical or systemic antipruritic agent (e.g. antihistamines, doxepin, GABA analogs) preceding study entry is permissible, but no new prescribed or over the counter topical or systemic anti-pruritics started post-enrollment
  • (ECOG) performance status of 0-2
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Any oral retinoid therapy for any indication within 3 weeks of the first dose of study drug
  • Prior TSEB (prior focal skin-directed RT acceptable)
  • Concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL) or another non-Hodgkin lymphoma
  • Concurrent diagnosis of additional non-skin
  • Pregnancy
  • Patients unwilling to use two forms of barrier while taking study medication
  • Receipt of treatment with another device or drug (at present or within 2 weeks of enrollment)
  • Familial hypertriglyceridemia or other medical conditions in which use of bexarotene would be
  • High likelihood of protocol non-compliance (in opinion of investigator)
  • Systemic within two weeks of first dose of study drug (patients on systemic steroids for non-disease related conditions will be permitted per investigator discretion)

Prohibited concurrent medications

  • Gemfibrozil is contraindicated as may increase bexarotene concentrations
  • Bexarotene is a minor substrate: avoid strong/moderate CYP3A4 inducers and inhibitors, if possible, but concomitant use is not a contraindication Bexarotene is a moderate CYP3A4 inducer: avoid concurrent administration with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate (e.g. cyclosporine, tacrolimus, sirolimus, quinidine, fentanyl), if possible
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Bexarotene Combined With Radiotherapy

    Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.

    Drug: Bexarotene · Radiation: Total Skin Electron Beam (TSEB)

Interventions

  • Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.

    Also known as: Targretin®

  • RadiationTotal Skin Electron Beam (TSEB)

    At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).

07

What researchers measure

Primary outcomes

  1. Incidence of radiation dermatitis grade 3+

    as defined by number of patients who develop CTCAE, v. 5, grade 3+ toxicities at 1 month post-treatment.

    Time frame: 1 month post-treatment

Secondary outcomes

  1. Overall skin response rate

    For patients with mycosis fungoides without blood involvement, the response criteria will be based upon modified international consensus guidelines.26 Specifically, skin response will be assessed by the Modified Severity Weighted Assessment Tool (mSWAT). For the purposes of this protocol, overall skin response will be considered to be either CR or PR.

    Time frame: up to 82 days post-TSEB

08

Study locations

3 of 3 sites recruiting
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Brandon Imber, MD · Contact631-212-6346
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Brandon Imber, MD · Contact631-212-6346
    • Shamir Geller · Contactgellers@mskcc.org
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Brandon Imber, MD · Contact631-212-6346
09

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 60 months after the start.

Of 29 phase 1 interventional studies under Mycosis Fungoides, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Mar 25, 2022
StartActual
Mar 16, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05296304
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Mar 16, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Brandon Imber, MD, MS
Contact
imberb@mskcc.org
631-212-6346
Shamir Geller
Contact
gellers@mskcc.org
Brandon Imber, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexarotene

Start the discussion